FDA Approves Monthly Olanzapine Injectable for Schizophrenia
The FDA has approved Weltruza, an extended-release olanzapine injectable given subcutaneously once a month, for schizophrenia. The decision adds another long-acting injectable option and may renew debate over whether such formulations should be used routinely.
The FDA has cleared Weltruza, a long-acting injectable form of olanzapine, for schizophrenia. It is designed to release the drug over an extended period and is given as a subcutaneous injection once a month.
The approval expands the set of long-acting injectable treatments available for schizophrenia. It may also renew discussion about whether such formulations should become routine practice.
People with schizophrenia and their caregivers may gain another monthly option, potentially altering some treatment routines. Clinicians may revisit when long-acting injectables are appropriate, while health systems could consider how broader use might affect care delivery. The renewed debate may shape patient and provider expectations, though individual needs and preferences would likely remain central. How widely the option is adopted could depend on factors beyond the approval itself.